AI-Based Microbiome Platforms Market Top Companies Study - Viome Life Sciences, Eagle Genomics Ltd., Microba Life Sciences, CosmosID.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global AI-Based Microbiome Platforms Market Size, Share & Trends Analysis Report By Microbiome Type (Gut Microbiome, Skin Microbiome, Oral Microbiome, And Environmental Microbiome), Deployment Mode (Cloud-Based, On-Premises, And Hybrid Models), Application (Drug Discovery & Development, Precision Medicine & Personalized Nutrition, Clinical Diagnostics, Consumer Microbiome & Wellness Platform, And Others), End-User (Pharmaceutical & Biotechnology Companies, Clinical & Diagnostic Laboratories, Research & Academic Institutes, Food & Nutrition Companies, And Others),- Market Outlook And Industry Analysis 2035"

AI-Based Microbiome Platforms Market Size is valued at USD 0.66 Bn in 2025 and is predicted to reach USD 2.23 Bn by the year 2035 at a 13.2% CAGR during the forecast period for 2026 to 2035.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com//request-sample/3640

AI-based microbiome platforms bring together the power of computing technology with microbiome science to perform analyses on complex datasets of microorganisms and gain valuable biological insights. Such platforms leverage artificial intelligence, machine learning, deep learning, and bioinformatics to process the data gathered through sequencing in the gut, skin, mouth, and other microbiomes. They provide researchers with an ability to detect microbial biomarkers, assess the risk of diseases, refine the development of therapies, and facilitate the progress of precision medicine.

With the rapid evolution of microbiome research, such platforms become increasingly popular in the work of healthcare organizations, pharmaceutical and biotech companies, and educational establishments. With the growing popularity of next-generation sequencing (NGS) and multi-omics technologies, there is an explosion of the amount of data gathered within microbiome research that requires sophisticated computational analysis. AI-based microbiome platforms dramatically decrease the time spent on analysis of microbiome datasets, improve its accuracy, and enhance predictive abilities.

Pharmaceutical and biotech companies increasingly use them to speed up drug discovery based on the findings of microbiome research, discover new targets for therapy, refine the design of clinical trials, and personalize treatments. With growing investments in precision medicine, computational biology, and artificial intelligence, the growth of the market is getting even more support. The algorithms used in machine learning help to continuously improve the accuracy of microbial classification, annotation of functions, and predictive disease modeling. Moreover, cloud-based AI solutions help to foster international cooperation through secure sharing of microbiome data between different organizations.

List of Prominent Players in the AI-Based Microbiome Platforms Market:
• Viome Life Sciences
• Eagle Genomics Ltd.
• Microba Life Sciences
• CosmosID
• Second Genome
• DayTwo Ltd.
• Phylagen Inc.
• QIAGEN N.V.
• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Oxford Nanopore Technologies plc
• Charles River Laboratories
• Eurofins Scientific
• Novogene Co., Ltd.
• BaseClear B.V.
• Biotia Inc.
• Ginkgo Bioworks
• Seed Health
• Zymo Research Corporation
• DNAnexus
• NVIDIA Corporation
• Microsoft Corporation
• Google Cloud
• BioGaia AB
• Resphera Biosciences

Add our site to Google Preferred Sources for quality content: https://google.com/preferences/source?q=insightaceanalytic.com

Market Dynamics:
Drivers:
AI-Based Microbiome Platforms Market growth is driven by increased sequencing efforts in microbiome studies, increased use of precision medicine, and investment in artificial intelligence in life sciences. Increased amount of sequencing data in microbiome is driving the need for advanced AI-based analytical tools that can process and analyze biological information that is very complicated. Advanced machine learning and deep learning algorithms help in detecting microbial biomarkers, predicting the progression of disease, and developing personalized treatment solutions.

Increasing use of AI-based microbiome platforms in drug discovery and development of pharmaceutical and biotech companies for the advancement of their R&D programs and drug development. With the help of these platforms, the companies are able to reduce time in performing microbial classification, functional analysis, biomarker discovery, and prediction activities. Further, development in high-performance computing and cloud computing is helping researchers analyze the genomic data effectively.

Challenges:
Even though the growth outlook is rather positive, there are some factors that prevent AI microbiome platforms from widespread use. The first issue relates to the difficulty of interpreting microbiome data using artificial intelligence. Each person's microbial community differs depending on his/her genetic profile, nutrition, lifestyle, environment, and geography. Thus, it is challenging to create universal AI prediction models.

The second issue is related to the lack of standardized protocols in collecting samples, sequencing methods, microbiome annotation, and data analysis. Different methods used in different laboratories result in inconsistency in the datasets that makes the research less reproducible and less practical in a clinical setting. Besides, combining the information obtained through different sequencing technologies involves complicated bioinformatics technology and personnel.

Regional Trends:
North America held the largest regional market share in the AI-Based Microbiome Platforms Market during 2025 attributed to the availability of leading biotech companies, well-established sequencing facilities, and substantial investments in AI and precision medicine. The US remains at the forefront of microbiome studies thanks to collaborations between pharmaceutical firms, research institutes, and healthcare institutions. Moreover, the region experiences positive funding, active venture capitalism, and rising use of cloud bioinformatics solutions.

Another regional market that can be highlighted includes Europe which features the development of genomics research, microbiome programs funded by governments, and growing investments into personalized medicine. Germany, the UK, France, and the Netherlands further improve their skills in AI-enabled life science research and computational biology.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period due to rising biotech investments, digitalization of healthcare, increasing genomics research, and growing government funding for AI. China, Japan, South Korea, and India feature a rising number of microbiome studies thanks to well-developed sequencing infrastructure and rising pharmaceutical R&D spending.

Customize this Study according to your Requirements @ https://www.insightaceanalytic.com/customization/3640

Recent Developments:
• May 2025: Eagle Genomics Ltd. has improved its AI-based knowledge discovery platform by incorporating sophisticated multi-omics integration technology for microbiome research. The upgraded version now allows scientists to integrate microbiome, genomic, metabolomics, and clinical data, thus accelerating biomarker discovery and precision medicine development.
• April 2025: Viome Life Sciences added more functionalities to its AI-based health intelligence platform with new analytics related to the microbiome that helps in developing personalized nutrition and wellness recommendations along with assessing the patient's risk of developing different diseases. The platform uses sophisticated machine learning models to develop individual health insights based on microbiome sequencing data.
• September 2024: Microba Life Sciences has expanded its precision microbiome solutions portfolio through increased cooperation with pharmaceutical and biotech companies that will enable AI-driven microbiome research and biomarker discovery.
• June 2024: QIAGEN N.V. developed advanced bioinformatics software with integrated artificial intelligence and machine learning tools for microbiome data analysis.

Segmentation of AI-Based Microbiome Platforms Market-
By Microbiome Type -
• Gut Microbiome
• Skin Microbiome
• Oral Microbiome
• Environment Microbiome
By Deployment Mode-
• Cloud
• On-premises
• Hybrid Models
By Application-
• Drug Discovery & Development
• Clinical Diagnostics
• Precision Medicine & Personalized Nutrition
• Consumer Microbiome & Wellness Platform
• Others
By End-user-
• Pharma & Biotechnology Companies
• Clinical & Diagnostic Laboratories
• Resraech & Academic Institutes
• Food & Nutrition Companies
• Others
By Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Comprehensive Report Overview: https://www.insightaceanalytic.com/report/ai-based-microbiome-platforms-market/3640

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.